<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>PIPRACIL- piperacillin sodiumÂ injection, powder, lyophilized, for solutionÂ </strong><br>Wyeth Pharmaceuticals, Inc.<br></p></div>
<h1>PIPRACIL<span class="Sup">Â®</span><br>(piperacillin for injection)<br>For Intravenous and Intramuscular Use </h1>
<div class="Contents">
<div class="Section">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="e1"></a><a name="section-2"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">Rx only </span></p>
<p>To reduce the development of drug-resistant bacteria and
maintain the effectiveness of PIPRACIL and other antibacterial drugs,
PIPRACIL should only be used to treat or prevent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are
proven or strongly suspected to be caused by bacteria.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="s1"></a><a name="section-3"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">PIPRACIL, sterile piperacillin sodium, is a semisynthetic
broad-spectrum penicillin for parenteral use derived from D(-)-Î±-aminobenzylpenicillin.
The chemical name of piperacillin sodium is sodium (2<span class="Italics">S</span>,5<span class="Italics">R</span>,6<span class="Italics">R</span>)-6-[(<span class="Italics">R</span>)-2-(4-ethyl-2,3-dioxo-1-piperazinecarboxamido)-2-phenylacetamido]-3,-3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate.
The chemical formula is C<span class="Sub">23</span>H<span class="Sub">26</span>N<span class="Sub">5</span>NaO<span class="Sub">7</span>S, and the molecular weight is 539.54. Its structural formula
is:<a name="f1"></a><img alt="Image from Drug Label Content" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=FAC0C875-111E-4AF2-D186-ED4D4EE9DE59&amp;name=pipracil-01.jpg"></p>
<p>Piperacillin sodium powder is a white to off-white
solid having the characteristic appearance of products prepared by
freeze-drying. It is freely soluble in water and in alcohol. The pH
of an aqueous solution containing 400 milligrams per milliliter ranges
from 5.5 to 7.5. OneÂ g contains 1.85Â mEqÂ (42.5Â mg)
of sodium (Na<span class="Sup">+</span>).</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="s2"></a><a name="section-4"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s3"></a><a name="section-4.1"></a><p></p>
<h2>Intravenous Administration:</h2>
<p class="First">In healthy adult volunteers, mean serum piperacillin
concentrations immediately after a twoâ€‘toÂ threeâ€‘minute
intravenous injection of 2, 4, or 6 g were 305, 412, and 775Â Î¼g/mL,
respectively. Serum concentrations lack dose proportionality.</p>
<table rules="all" width="100.00%">
<col align="left" width="6.530%">
<col align="left" width="7.768%">
<col align="left" width="7.791%">
<col align="left" width="7.768%">
<col align="left" width="7.806%">
<col align="left" width="7.783%">
<col align="left" width="7.806%">
<col align="left" width="7.806%">
<col align="left" width="7.783%">
<col align="left" width="7.806%">
<col align="left" width="7.783%">
<col align="left" width="7.806%">
<col align="left" width="7.760%">
<thead><tr class="First Last"><td class="Lrule Rrule" align="center" colspan="13" valign="top">
<span class="Bold">PIPERACILLIN SERUM CONCENTRATIONS IN ADULTS
(Î¼</span><span class="Bold">g/mL) AFTER A TWO- TO
THREE-MINUTE I.V. INJECTION </span>
</td></tr></thead>
<tbody>
<tr class="First">
<td class="Lrule" align="left" valign="top"><span class="Bold">DOSE</span></td>
<td align="left" valign="top"><span class="Bold"><span class="Underline">0</span></span></td>
<td align="left" valign="top"><span class="Bold"><span class="Underline">10 min</span></span></td>
<td align="left" valign="top"><span class="Bold"><span class="Underline">20 min</span></span></td>
<td align="left" valign="top"><span class="Bold"><span class="Underline">30 min</span></span></td>
<td align="left" valign="top"><span class="Bold"><span class="Underline">1 h</span></span></td>
<td align="left" valign="top"><span class="Bold"><span class="Underline">1.5 h</span></span></td>
<td align="left" valign="top"><span class="Bold"><span class="Underline">2 h</span></span></td>
<td align="left" valign="top"><span class="Bold"><span class="Underline">3 h</span></span></td>
<td align="left" valign="top"><span class="Bold"><span class="Underline">4 h</span></span></td>
<td align="left" valign="top"><span class="Bold"><span class="Underline">6 h</span></span></td>
<td align="left" valign="top"><span class="Bold"><span class="Underline">8 h</span></span></td>
<td class="Rrule" align="left" valign="top"></td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top">2 </td>
<td align="left" valign="top">305 <br>(159-<br>615) </td>
<td align="left" valign="top">202<br>(164-<br>225)  </td>
<td align="left" valign="top">156 <br>(52-<br>165) </td>
<td align="left" valign="top">67 <br>(41-<br>88) </td>
<td align="left" valign="top">40 <br>(25-<br>57) </td>
<td align="left" valign="top">24 <br>(18-<br>31) </td>
<td align="left" valign="top">20 <br>(14-<br>24) </td>
<td align="left" valign="top">8 <br>(3-<br>11) </td>
<td align="left" valign="top">3 <br>(2-<br>4) </td>
<td align="left" valign="top">2 <br>(â‰¤0.6-<br>3) </td>
<td align="left" valign="top">â€”<br>
</td>
<td class="Rrule" align="left" valign="top"></td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top">4 </td>
<td align="left" valign="top">412 <br>(389-<br>484) </td>
<td align="left" valign="top">344 <br>(315-<br>379) </td>
<td align="left" valign="top">295 <br>(269-<br>330) </td>
<td align="left" valign="top">117 <br>(98-<br>138) </td>
<td align="left" valign="top">93 <br>(78-<br>110) </td>
<td align="left" valign="top">60 <br>(50-<br>67) </td>
<td align="left" valign="top">36 <br>(26-<br>51) </td>
<td align="left" valign="top">20 <br>(17-<br>24) </td>
<td align="left" valign="top">8 <br>(7-<br>11) </td>
<td align="left" valign="top">4 <br>(3.7-<br>4.1) </td>
<td align="left" valign="top">0.9 <br>(0.7-<br>1) </td>
<td class="Rrule" align="left" valign="top"></td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top">6 </td>
<td align="left" valign="top">775 <br>(695-<br>849) </td>
<td align="left" valign="top">609 <br>(530-<br>670) </td>
<td align="left" valign="top">563 <br>(492-<br>630) </td>
<td align="left" valign="top">325 <br>(292-<br>363) </td>
<td align="left" valign="top">208 <br>(180-<br>239) </td>
<td align="left" valign="top">138 <br>(115-<br>175) </td>
<td align="left" valign="top">90 <br>(71-<br>113) </td>
<td align="left" valign="top">38 <br>(29-<br>53) </td>
<td align="left" valign="top">33 <br>(25-<br>44) </td>
<td align="left" valign="top">8 <br>(3-<br>19) </td>
<td align="left" valign="top">3.2 <br>(&lt;2-<br>6)</td>
<td class="Rrule" align="left" valign="top"></td>
</tr>
<tr class="Botrule Lrule Rrule Toprule"><td class="Botrule Lrule Rrule Toprule" align="center" colspan="13" valign="top">
<span class="Bold">PIPERACILLIN SERUM CONCENTRATIONS
IN ADULTS (Î¼</span><span class="Bold">g/mL) AFTER
A 30-MINUTE I.V. INFUSION</span>
</td></tr>
<tr>
<td class="Lrule" align="left" valign="top"><span class="Bold">DOSE</span></td>
<td align="left" valign="top"><span class="Bold"><span class="Underline">0</span></span></td>
<td align="left" valign="top"><span class="Bold"><span class="Underline">5 min</span></span></td>
<td align="left" valign="top"><span class="Bold"><span class="Underline">10 min</span></span></td>
<td align="left" valign="top"><span class="Bold"><span class="Underline">15 min</span></span></td>
<td align="left" valign="top"><span class="Bold"><span class="Underline">30 min</span></span></td>
<td align="left" valign="top"><span class="Bold"><span class="Underline">45 min</span></span></td>
<td align="left" valign="top"><span class="Bold"><span class="Underline">1 h</span></span></td>
<td align="left" valign="top"><span class="Bold"><span class="Underline">1.5 h</span></span></td>
<td align="left" valign="top"><span class="Bold"><span class="Underline">2 h</span></span></td>
<td align="left" valign="top"><span class="Bold"><span class="Underline">4 h</span></span></td>
<td align="left" valign="top"><span class="Bold"><span class="Underline">6 h</span></span></td>
<td class="Rrule" align="left" valign="top"><span class="Bold"><span class="Underline">7.5 h</span></span></td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top">4 </td>
<td align="left" valign="top">244 <br>(155-<br>298) </td>
<td align="left" valign="top">215 <br>(169-<br>247) </td>
<td align="left" valign="top">186 <br>(140-<br>209) </td>
<td align="left" valign="top">177 <br>(142-<br>213) </td>
<td align="left" valign="top">141 <br>(122-156) </td>
<td align="left" valign="top">146 <br>(110-<br>265) </td>
<td align="left" valign="top">105 <br>(85-<br>133) </td>
<td align="left" valign="top">72 <br>(53-<br>105) </td>
<td align="left" valign="top">53 <br>(36-<br>69) </td>
<td align="left" valign="top">15 <br>(6-<br>24) </td>
<td align="left" valign="top">4 <br>(1-<br>9) </td>
<td class="Rrule" align="left" valign="top">2 <br>(0.5-<br>3) </td>
</tr>
<tr class="Last">
<td class="Lrule" align="left" valign="top">6 </td>
<td align="left" valign="top">353 <br>(324-<br>371) </td>
<td align="left" valign="top">298 <br>(242-<br>339) </td>
<td align="left" valign="top">298 <br>(232-<br>331) </td>
<td align="left" valign="top">272 <br>(219-314) </td>
<td align="left" valign="top">229 <br>(185-<br>249) </td>
<td align="left" valign="top">180 <br>(144-<br>209) </td>
<td align="left" valign="top">149 <br>(117-<br>171) </td>
<td align="left" valign="top">104 <br>(89-<br>113) </td>
<td align="left" valign="top">73 <br>(66-<br>94) </td>
<td align="left" valign="top">22 <br>(12-<br>39) </td>
<td align="left" valign="top">16 <br>(5-<br>49) </td>
<td class="Rrule" align="left" valign="top">â€”<br>â€”</td>
</tr>
</tbody>
</table>
<p>A 30-minute infusion of 6Â g every 6Â h
gave, on the fourth day, a mean peak serum concentration of 420Â Î¼g/mL.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s4"></a><a name="section-4.2"></a><p></p>
<h2>Intramuscular Administration: </h2>
<p class="First">PIPRACIL is rapidly absorbed after intramuscular
injection. In healthy volunteers, the mean peak serum concentration
occurs approximately 30 minutes after a single dose of 2Â g and
is about 36 Î¼g/mL. The oral administration of 1 g probenecid
before injection produces an increase in piperacillin peak serum level
of about 30%. The area under the curve (AUC) is increased by approximately
60%. </p>
</div>
<div class="Section">
<a name="s5"></a><a name="section-4.3"></a><p></p>
<h2>Pharmacokinetics:</h2>
<p class="First">PIPRACIL is not absorbed when given orally. Peak
serum concentrations are attained approximately 30 minutes after intramuscular
injections and immediately after completion of intravenous injection
or infusion. The serum half-life in healthy volunteers ranges from
36Â minutes to one hour and 12 minutes. The mean elimination half-life
of PIPRACIL in healthyÂ adult volunteers is 54 minutes following
administration of 2Â g and 63 minutes following 6Â g. As with
other penicillins, PIPRACIL is eliminated primarily by glomerular
filtration and tubular secretion; it is excreted rapidly as unchanged
drug in high concentrations in the urine. Approximately 60% to 80%
of the administered dose is excreted in the urine in the first 24
hours. Piperacillin urine concentrations, determined by microbioassay,
are as high as 14,100Â Î¼g/mL following a 6-g intravenous
dose and 8,500Â Î¼g/mL following a 4-g intravenous dose.
These urine drug concentrations remain well above 1,000Â Î¼g/mL
throughout the dosing interval.</p>
</div>
<div class="Section">
<a name="s6"></a><a name="section-4.4"></a><p></p>
<h2>Distribution:</h2>
<p class="First">PIPRACIL binding to human serum proteins is 16%.
The drug is widely distributed in human tissues and body fluids, including
bone, prostate, and heart, and reaches high concentrations in bile.
After a 4-g bolus injection, maximum biliary concentrations average
3,205Â Î¼g/mL. It penetrates into the cerebrospinal fluid
in the presence of inflamed meninges.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s7"></a><a name="section-4.5"></a><p></p>
<h2>Special Populations: </h2>
<div class="Section" data-sectionCode="42229-5">
<a name="e7"></a><a name="section-4.5.1"></a><p></p>
<h3></h3>
<p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal Insufficiency</span>:</span> The elimination half-life is increased twofold in mild to moderate
<span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> and fivefold to sixfold in severe impairment. Because
PIPRACIL is excreted by the biliary route as well as by the renal
route, it can be used safely in appropriate dosage in patients with
severely restricted kidney function. (See <span class="Bold"><a href="#s33">DOSAGE AND ADMINISTRATION</a></span>.)</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="e8"></a><a name="section-4.5.2"></a><p></p>
<h3></h3>
<p class="First"><span class="Italics">Pediatric Patients:</span> After intravenous administration of 50Â mg/kg (5-minute infusion)
in neonates, the mean plasma concentration of piperacillin extrapolated
to time zero was 141Â Î¼g/mL, and the apparent volume of
distribution averaged 101Â mL/kg.</p>
<p>In premature
neonates, the mean elimination half-life has been reported to range
from 147Â toÂ 258Â minutes following administration of
a single intravenous dose of 75Â mg/kg, the halfâ€‘life decreasing
with increasing postnatal age. The changes in half-life appeared to
be caused byÂ an immature renal system during the first weeks
of life. In one study in neonates, the mean elimination half-life
ranged from 127 to 217 minutes following a single intravenous dose
of 50Â mg/kg. As in premature neonates, the half-life in neonates
decreased with increasing postnatal age. The mean total body clearance
in neonates has been reported to range from 32Â toÂ 41Â mL/min/1.73Â m<span class="Sup">2</span> after an intravenous dose of 50Â mg/kg.</p>
<p>Following administration of an intravenous dose of 50Â mg/kg
in older pediatric patients (fromÂ 1Â month up to 15Â years
of age), the mean elimination half-life has been reported to range
from 31Â to 37 minutes, and the mean total body clearance has
been reported to range from 124Â toÂ 160Â mL/min/1.73Â m<span class="Sup">2</span>.</p>
<p>As in adults, PIPRACIL elimination
tends to be prolonged in pediatric patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>.
In one study in pediatric patients (age range, 3.3 to 14.3 years),
the mean elimination half-life in patients with decreased renal function
was approximately 60 minutes versus 37 minutes in patients with normal
renal function. The elimination half-life has been reported to range
from 3.5 to 14 hours in neonates with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>.</p>
<p>Pharmacokinetic data have indicated that among pediatric
patients below 12 years of age, those with <span class="product-label-link" type="condition" conceptid="441267" conceptname="Cystic fibrosis">cystic fibrosis</span> have increased
bioavailability, lower serum concentrations, and increased total body
clearance of piperacillin compared to young, healthy pediatric volunteers
under 12Â years of age.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s8"></a><a name="section-5"></a><p></p>
<h1>MICROBIOLOGY</h1>
<p class="First">Piperacillin is an antibiotic which exerts its bactericidal
activity by inhibiting both septum and cell wall synthesis. It is
active against a variety of gram-positive and gram-negative aerobic
and anaerobic bacteria. Piperacillin has been shown to be active against
most <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the following microorganisms, both <span class="Italics">in vitro</span> and in clinical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>
as described in the <span class="Bold"><a href="#s12">INDICATIONS AND USAGE</a></span> section. </p>
<p><span class="Bold">Aerobic gram-positive microorganisms</span><br><span class="Italics">Enterococci,</span> including<span class="Italics"> Enterococcus faecalis</span><br><span class="Italics">Streptococcus pneumoniae</span><br><span class="Italics">Streptococcus pyogenes</span></p>
<p><span class="Bold">Aerobic gram-negative microorganisms</span><br><span class="Italics">Acinetobacter  </span> species<br><span class="Italics">Enterobacter  </span> species<br><span class="Italics">Escherichia coli</span><br><span class="Italics">Haemophilus influenzae</span> (non-Î²-lactamase-producing
<span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>)<br><span class="Italics">Klebsiella</span> species<br><span class="Italics">Morganella morganii</span><br><span class="Italics">Neisseria gonorrhoeae </span><br><span class="Italics">Proteus mirabilis  </span><br><span class="Italics">Proteus vulgaris</span><br><span class="Italics">Providencia rettgeri  </span><br><span class="Italics">Pseudomonas aeruginosa </span><br><span class="Italics">Serratia</span> species</p>
<p><span class="Bold">Anaerobic gram-positive microorganisms</span><br>Anaerobic cocci<br><span class="Italics">Clostridium</span> species</p>
<p><span class="Bold">Anaerobic
gram-negative microorganisms</span><br><span class="Italics">Bacteroides</span> species, including<span class="Italics"> Bacteroides fragilis</span></p>
<p>The following <span class="Italics">in vitro</span> data are available, <span class="Bold Underline">but their clinical significance is unknown.</span></p>
<p>At least 90% of the following microorganisms
exhibit an<span class="Italics"> in vitro </span>minimum
inhibitory concentration (MIC) less than or equal to the susceptible
breakpoint for piperacillin. However, the safety and effectiveness
of piperacillin in treating clinical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> due to these microorganisms
have not been established in adequate and well-controlled clinical
trials.</p>
<p><span class="Bold">Aerobic gram-positive
microorganisms</span><br><span class="Italics">Streptococcus
agalactiae</span><br><span class="Italics">Streptococcus
bovis </span><br><span class="Italics">Viridans</span> group<span class="Italics"> streptococci</span></p>
<p><span class="Bold">Aerobic gram-negative microorganisms</span><br><span class="Italics">Burkholderia cepacia</span><br><span class="Italics">Citrobacter diversus</span><br><span class="Italics">Citrobacter freundii</span><br><span class="Italics">Pseudomonas fluorescens</span><br><span class="Italics">Stenotrophomonas maltophilia</span><br><span class="Italics">Yersinia enterocolitica  </span></p>
<p><span class="Bold">Anaerobic gram-positive microorganisms</span><br><span class="Italics">Actinomyces  </span> species<br><span class="Italics">Eubacterium  </span> species</p>
<p><span class="Bold">Anaerobic gram-negative microorganisms</span><br><span class="Italics">Fusobacterium necrophorum</span><br><span class="Italics">Fusobacterium nucleatum</span><br><span class="Italics">Porphyromonas asaccharolytica</span><br><span class="Italics">Prevotella melaninogenica</span><br><span class="Italics">Veillonella</span> species</p>
<div class="Section">
<a name="s9"></a><a name="section-5.1"></a><p></p>
<h2>Susceptibility Testing Methods</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s10"></a><a name="section-5.1.1"></a><p></p>
<h3><span class="Bold"><span class="Italics">Dilution
Techniques:  </span></span></h3>
<p class="First">Quantitative methods are used to determine antimicrobial
<span class="product-label-link" type="condition" conceptid="4190299" conceptname="Broth microdilution susceptibility test">minimum inhibitory concentrations</span> (MICs). These MICs provide estimates
of the susceptibility of bacteria to antimicrobial compounds. The
MICs should be determined using a standardized procedure. Standardized
procedures are based on a dilution method<a href="#endnote1">1,2</a> (broth or agar) or equivalent with standardized inoculum
concentrations and standardized concentrations of piperacillin powder.
The MIC values should be interpreted according to the following criteria:</p>
<p>For testing<span class="Italics">Enterobacteriaceae </span> and <span class="Italics">Acinetobacter  </span> species:</p>
<table width="100.00%">
<col align="left" width="56.800%">
<col align="left" width="43.200%">
<thead><tr class="First Last">
<td align="center" valign="top">MIC (Î¼g/mL) </td>
<td align="left" valign="top">Interpretation </td>
</tr></thead>
<tbody><tr class="First Last">
<td align="center" valign="top">â‰¤ 16 <br>32-64 <br>â‰¥
128 </td>
<td align="left" valign="top">Susceptible (S) <br>Intermediate (I) <br>Resistant (R) </td>
</tr></tbody>
</table>
<p>For testing <span class="Italics">Pseudomonas
aeruginosa</span>:</p>
<table width="100.00%">
<col align="left" width="56.800%">
<col align="left" width="43.200%">
<thead><tr class="First Last">
<td align="center" valign="top">MIC (Î¼g/mL) </td>
<td align="left" valign="top">Interpretation </td>
</tr></thead>
<tbody><tr class="First Last">
<td align="center" valign="top">â‰¤ 64 <br>â‰¥ 128 </td>
<td align="left" valign="top">Susceptible (S) <br>Resistant (R) </td>
</tr></tbody>
</table>
<p>For testing<span class="Italics"> Enterococcus
faecalis</span><span class="Sup">a</span>:</p>
<table width="100.00%">
<col align="left" width="56.800%">
<col align="left" width="43.200%">
<thead><tr class="First Last">
<td align="center" valign="top">MIC (Î¼g/mL) </td>
<td align="left" valign="top">Interpretation </td>
</tr></thead>
<tfoot><tr class="First Last"><td align="left" colspan="2" valign="top"><p class="First Footnote"><span class="Sup">a</span> Penicillin susceptibility may be used to predict the
susceptibility to piperacillin.<a href="#endnote1">1,2</a></p></td></tr></tfoot>
<tbody><tr class="First Last">
<td align="center" valign="top">â‰¤ 8 <br>â‰¥ 16 </td>
<td align="left" valign="top">Susceptible (S) <br>Resistant (R) </td>
</tr></tbody>
</table>
<p><span class="Italics">Haemophilus </span> species are considered susceptible if the MIC of piperacillin isâ‰¤ to 1 Î¼g/mL.*</p>
<p>* Dilution methods
such as those described in the International Collaborative Study (ActaÂ PatholÂ Microbiol
ScandÂ [B]Â 1971; supplÂ 217) have been used to determine
susceptibility of organisms to piperacillin.</p>
<p>Dilution (MICs) susceptibility test methods and interpretative criteria
for assessing the susceptibility of <span class="Italics">Neisseria
gonorrhoeae </span>to piperacillin have not been established. However,Î²â€‘lactamase testing will detect one form of penicillin
resistance in <span class="Italics">Neisseria gonorrhoeae </span>and is recommended.<a href="#endnote1">1,2</a></p>
<p>Dilution (MICs) susceptibility test methods and interpretative
criteria for assessing the susceptibility of <span class="Italics">Streptococcus pneumoniae  </span>and <span class="Italics">Streptococcus pyogenes </span>to piperacillin have not been established.<a href="#endnote1">1,2</a></p>
<p>A report ofâ€œSusceptibleâ€? indicates that the pathogen is likely
to be inhibited if the antimicrobial compound in the blood reaches
the concentrations usually achievable. A report of â€œIntermediateâ€?
indicates that the result should be considered equivocal, and, if
the microorganism is not fully susceptible to alternative, clinically
feasible drugs, the test should be repeated. This category implies
possible clinical applicability in body sites where the drug is physiologically
concentrated or in situations where high dosage of drug can be used.
This category also provides a buffer zone which prevents small uncontrolled
technical factors from causing major discrepancies in interpretation.
A report of â€œResistantâ€? indicates that the pathogen
is not likely to be inhibited if the antimicrobial compound in the
blood reaches the concentrations usually achievable; other therapy
should be selected.</p>
<p><span class="Bold Italics">Quality Control:</span></p>
<p>Standardized susceptibility test procedures require the use of laboratory
control microorganisms to control the technical aspects of the laboratory
procedures. Standard piperacillin powder should provide the following
MIC values:</p>
<table width="100.00%">
<col align="left" width="37.012%">
<col align="left" width="20.407%">
<col align="left" width="42.581%">
<thead><tr class="First Last">
<td align="left" valign="top">Microorganism </td>
<td align="left" valign="top"></td>
<td align="center" valign="top">MIC (Î¼g/mL) </td>
</tr></thead>
<tbody><tr class="First Last">
<td align="left" valign="top">
<span class="Italics">Enterococcus
faecalis</span><br><span class="Italics">Escherichia coli</span><br><span class="Italics">Pseudomonas aeruginosa</span>
</td>
<td align="left" valign="top">ATCC 29212 <br>ATCC 25922<br>ATCC
27853 </td>
<td align="center" valign="top">1-4 <br>1-4 <br>1-8 </td>
</tr></tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s11"></a><a name="section-5.1.2"></a><p></p>
<h3><span class="Italics">Diffusion Techniques:</span></h3>
<p class="First">Quantitative methods that require measurement of
zone diameters also provide reproducible estimates of the susceptibility
of bacteria to antimicrobial compounds. One such standardized procedure<a href="#endnote2">2,3</a> requires the use of standardized inoculum
concentrations. This procedure uses paper disks impregnated with 100Î¼g of piperacillin to test the susceptibility of microorganisms
to piperacillin.</p>
<p>Reports from the laboratory
providing results of the standard single-disk susceptibility test
with a 100Â Î¼g piperacillin disk should be interpreted according
to the following criteria:</p>
<p>For testing <span class="Italics">Enterobacteriaceae</span> and <span class="Italics">Acinetobacter</span> species:</p>
<table width="100.00%">
<col align="left" width="59.850%">
<col align="left" width="40.150%">
<thead><tr class="First Last">
<td align="center" valign="top">Zone Diameter (mm) </td>
<td align="left" valign="top">Interpretation </td>
</tr></thead>
<tbody><tr class="First Last">
<td align="center" valign="top">â‰¥ 21 <br>18-20 <br>â‰¤
17 </td>
<td align="left" valign="top">Susceptible (S) <br>Intermediate (I) <br>Resistant (R) </td>
</tr></tbody>
</table>
<p>For testing <span class="Italics">Pseudomonas
aeruginosa</span>:</p>
<table width="100.00%">
<col align="left" width="59.850%">
<col align="left" width="40.150%">
<thead><tr class="First Last">
<td align="center" valign="top">Zone Diameter (mm) </td>
<td align="left" valign="top">Interpretation </td>
</tr></thead>
<tbody><tr class="First Last">
<td align="center" valign="top">â‰¥ 18 <br>â‰¤ 17 </td>
<td align="left" valign="top">Susceptible (S) <br>Resistant (R) </td>
</tr></tbody>
</table>
<p>For testing <span class="Italics">Enterococcus
faecalis</span><span class="Sup">b</span>:</p>
<table width="100.00%">
<col align="left" width="59.850%">
<col align="left" width="40.150%">
<thead><tr class="First Last">
<td align="center" valign="top">Zone Diameter (mm) </td>
<td align="left" valign="top">Interpretation </td>
</tr></thead>
<tfoot><tr class="First Last"><td align="left" colspan="2" valign="top"><p class="First Footnote"><span class="Sup">b</span> Penicillin susceptibility may be used to predict the
susceptibility to piperacillin.<a href="#endnote2">2,3</a></p></td></tr></tfoot>
<tbody><tr class="First Last">
<td align="center" valign="top">â‰¥ 15 <br>â‰¤ 14 </td>
<td align="left" valign="top">Susceptible (S) <br>Resistant (R) </td>
</tr></tbody>
</table>
<p><span class="Italics">Haemophilus </span>species which give zones of â‰¥Â 29Â mm are susceptible;
resistant <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> give zones of â‰¤Â 28Â mm. The above
interpretive criteria are based on the use of the standardized procedure.
Antibiotic susceptibility testing requires carefully prescribed procedures.
Susceptibility tests are biased to a considerable degree when different
methods are used.</p>
<p>NCCLS Approved Standard; M2-A2
(Formerly ASM-2) Performance Standards for Antimicrobic Disk Susceptibility
Tests, Second Edition, available from the National Committee of Clinical
Laboratory Standards.</p>
<p>Disk diffusion (zone diameters)
susceptibility test methods and interpretative criteria for assessing
the susceptibility of <span class="Italics">Neisseria gonorrhoeae</span> to piperacillin have not been established. However, Î²-lactamase
testing to penicillin is recommended. It will detect one form of penicillin
resistance, chromosomally mediated resistance, in <span class="Italics">Neisseria gonorrhoeae</span>. In addition,
gonococci with 10-unit penicillin disk zone diameters of â‰¤Â 19
mm are likely to be Î²-lactamase producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> (plasmid-mediated
penicillin resistance).<a href="#endnote2">2,3</a></p>
<p>Disk diffusion (zone diameters) susceptibility test methods
and interpretative criteria for assessing the susceptibility of <span class="Italics">Streptococcus pneumoniae</span> and <span class="Italics">Streptococcus pyogenes  </span> to piperacillin
have not been established.<a href="#endnote2">2,3</a></p>
<p>Interpretation should be as stated above for
results using dilution techniques. Interpretation involves correlation
of the diameter obtained in the disk test with the MIC for piperacillin.</p>
<p><span class="Bold Italics">Quality Control:</span><br>As with standardized dilution techniques, diffusion methods
require the use of laboratory control microorganisms that are used
to control the technical aspects of the laboratory procedures. For
the diffusion technique, the 100-Î¼g piperacillin disk should
provide the following zone diameters in these laboratory test quality
control <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>:</p>
<table width="100.00%">
<col align="left" width="37.012%">
<col align="left" width="20.407%">
<col align="left" width="42.581%">
<thead><tr class="First Last">
<td align="left" valign="top">Microorganism </td>
<td align="left" valign="top"></td>
<td align="center" valign="top">Zone Diameter (mm) </td>
</tr></thead>
<tbody><tr class="First Last">
<td align="left" valign="top">
<span class="Italics">Escherichia
coli</span><br><span class="Italics">Pseudomonas aeruginosa</span>
</td>
<td align="left" valign="top">ATCC 25922 <br>ATCC 27853 </td>
<td align="center" valign="top">24-30 <br>25-33 </td>
</tr></tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="e10"></a><a name="section-5.1.3"></a><p></p>
<h3><span class="Bold"><span class="Italics">Anaerobic
Techniques:  </span></span></h3>
<p class="First">For anaerobic bacteria, the susceptibility to piperacillin
as MICs can be determined by standardized test methods.<a href="#endnote4">4</a> The MIC values obtained should be interpreted
according to the following criteria:</p>
<table width="100.00%">
<col align="left" width="56.800%">
<col align="left" width="43.200%">
<thead><tr class="First Last">
<td align="center" valign="top">MIC (Î¼g/mL) </td>
<td align="left" valign="top">Interpretation </td>
</tr></thead>
<tbody><tr class="First Last">
<td align="center" valign="top">â‰¤ 32 <br> 64 <br>â‰¥
128 </td>
<td align="left" valign="top">Susceptible (S) <br>Intermediate (I) <br>Resistant (R) </td>
</tr></tbody>
</table>
<p>Interpretation is identical to that stated above
for results using dilution techniques.</p>
<p>As with
other susceptibility techniques, the use of laboratory control microorganisms
is required to control the technical aspects of the laboratory standardized
procedures. Standardized piperacillin powder should provide the following
MIC values:</p>
<table width="100.00%">
<col align="left" width="39.920%">
<col align="left" width="19.327%">
<col align="left" width="40.753%">
<thead><tr class="First Last">
<td align="left" valign="top">Microorganism </td>
<td align="left" valign="top"></td>
<td align="center" valign="top">MIC (Î¼g/mL) </td>
</tr></thead>
<tfoot><tr class="First Last"><td align="left" colspan="3" valign="top"><p class="First Footnote"><span class="Sup">c</span> This quality control range is applicable only to tests
performed using either <span class="Italics">Brucella</span> blood agar or Wilkins-Chalgren agar with the Reference Agar Dilution
Method.<a href="#endnote4">4</a><br><span class="Sup">d</span> This
quality range is applicable only to tests performed in the broth formulation
of Wilkins-Chalgren agar with the Broth microdilution method.<a href="#endnote4">4</a></p></td></tr></tfoot>
<tbody><tr class="First Last">
<td align="left" valign="top">
<span class="Italics">Bacteroides
fragilis</span><span class="Sup">c</span><br><span class="Italics">Bacteroides
thetaiotaomicron</span><span class="Sup">d</span>
</td>
<td align="left" valign="top">ATCC 25285 <br>ATCC 29741 </td>
<td align="center" valign="top">2-8 <br>8-32 </td>
</tr></tbody>
</table>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="s12"></a><a name="section-6"></a><p></p>
<h1>INDICATIONS AND USAGE </h1>
<p class="First"><span class="Italics">Therapeutic:</span> PIPRACIL is indicated for the treatment of serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> caused
by susceptible <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the designated microorganisms in the conditions
listed below:</p>
<p><span class="Italics">Intra-Abdominal
<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></span> including hepatobiliary and surgical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>
caused by <span class="Italics">E. coli</span>, <span class="Italics">Pseudomonas aeruginosa</span>, enterococci, <span class="Italics">Clostridium</span> spp., anaerobic cocci, or <span class="Italics">Bacteroides</span> spp., including <span class="Italics">B. fragilis.</span></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary Tract Infections</span></span> caused by <span class="Italics">E. coli</span>, <span class="Italics">Klebsiella</span> spp., <span class="Italics">P. aeruginosa</span>, <span class="Italics">Proteus</span> spp., including <span class="Italics">P. mirabilis</span>, or enterococci.</p>
<p><span class="Italics">Gynecologic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></span> including <span class="product-label-link" type="condition" conceptid="4302765" conceptname="Endometritis">endometritis</span>, <span class="product-label-link" type="condition" conceptid="199067" conceptname="Inflammatory disease of female pelvic organs AND/OR tissues">pelvic inflammatory disease</span>, pelvic <span class="product-label-link" type="condition" conceptid="435613" conceptname="Cellulitis">cellulitis</span>
caused by <span class="Italics">Bacteroides</span> spp.,
including <span class="Italics">B. fragilis</span>, anaerobic
cocci, <span class="Italics">Neisseria gonorrhoeae</span>, or enterococci (<span class="Italics">E. faecalis</span>). </p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">Septicemia</span></span> including <span class="product-label-link" type="condition" conceptid="132736" conceptname="Bacteremia">bacteremia</span> caused by <span class="Italics">E. coli</span>, <span class="Italics">Klebsiella  </span>spp., <span class="Italics">Enterobacter</span> spp., <span class="Italics">Serratia </span>spp., <span class="Italics">P. mirabilis</span>, <span class="Italics">S. pneumoniae</span>, enterococci, <span class="Italics">P. aeruginosa</span>, <span class="Italics">Bacteroides </span> spp., or anaerobic
cocci.</p>
<p><span class="Italics">Lower RespiratoryTract <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></span> caused by <span class="Italics">E. coli</span>, <span class="Italics">Klebsiella</span> spp., <span class="Italics">Enterobacter</span> spp., <span class="Italics">P</span>.Â <span class="Italics">aeruginosa</span>, <span class="Italics">Serratia</span> spp., <span class="Italics">H. influenzae</span>, <span class="Italics">Bacteroides</span> spp., or anaerobic cocci.
Although improvement has been noted in patients with <span class="product-label-link" type="condition" conceptid="441267" conceptname="Cystic fibrosis">cystic fibrosis</span>,
lasting bacterial eradication may not necessarily be achieved.</p>
<p><span class="Italics">Skin and Skin Structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></span> caused by <span class="Italics">E. coli</span>, <span class="Italics">Klebsiella</span> spp., <span class="Italics">Serratia</span> spp., <span class="Italics">Acinetobacter  </span>Â spp., <span class="Italics">Enterobacter</span> spp., <span class="Italics">P. aeruginosa</span>, <span class="Italics">Morganella morganii</span>, <span class="Italics">ProvidenciaÂ rettgeri</span>, <span class="Italics">Proteus vulgaris</span>, <span class="Italics">P. mirabilis</span>, <span class="Italics">Bacteroides</span> spp., including <span class="Italics">B. fragilis</span>, anaerobic cocci, or enterococci.</p>
<p><span class="Italics">Bone and <span class="product-label-link" type="condition" conceptid="4180167" conceptname="Infectious disorder of joint">Joint Infections</span> </span>caused by <span class="Italics">P. aeruginosa</span>, enterococci, <span class="Italics">Bacteroides</span> spp., or anaerobic cocci.</p>
<p>Uncomplicated Gonococcal <span class="product-label-link" type="condition" conceptid="195862" conceptname="Urethritis">Urethritis</span> caused by <span class="Italics">N. gonorrhoeae.</span></p>
<p>PIPRACIL has also been shown to be clinically effective for the treatment
of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> at various sites caused by <span class="Italics">Streptococcus</span> species including <span class="Italics">S. pyogenes</span> and <span class="Italics">S. pneumoniae</span>; however, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> caused by these organisms are ordinarily treated
with more narrow spectrum penicillins. Because of its broad spectrum
of bactericidal activity against gram-positive and gram-negative aerobic
and anaerobic bacteria, PIPRACIL is particularly useful for the treatment
of mixed <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> and presumptive therapy prior to the identification
of the causative organisms. </p>
<p>Also, PIPRACIL
may be administered as single drug therapy in some situations where
normally two antibiotics might be employed.</p>
<p>Piperacillin has been successfully used with aminoglycosides, especially
in patients with impaired host defenses. Both drugs should be used
in full therapeutic doses.</p>
<p>Appropriate cultures
should be made for susceptibility testing before initiating therapy
and therapy adjusted, if appropriate, once the results are known.</p>
<p><span class="Italics">Prophylaxis:</span> PIPRACIL
is indicated for <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> use in surgery including intra-abdominal
(gastrointestinal and biliary) procedures, vaginal hysterectomy, abdominal
hysterectomy, and cesarean section. Effective <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> use depends
on the time of administration; PIPRACIL should be given one-half to
one hour before the operation so that effective levels can be achieved
in the site prior to the procedure.</p>
<p>The <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> use of piperacillin should be stopped within 24
hours, since continuing administration of any antibiotic increases
the possibility of adverse reactions, but in the majority of surgical
procedures, does not reduce the incidence of subsequent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>.
If there are signs of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, specimens for culture and susceptibility
testing should be obtained for identification of the causative microorganism
so that appropriate therapy can be instituted.</p>
<p>To reduce the development of drug-resistant bacteria and maintain
the effectiveness of PIPRACIL and other antibacterial drugs, PIPRACILshould only be used to treat or prevent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven
or strongly suspected to be caused by susceptible bacteria. When culture
and susceptibility information are available, they should be considered
in selecting or modifying antibacterial therapy. In the absence of
such data, local epidemiology and susceptibility patterns may contribute
to the empiric selection of therapy.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="s13"></a><a name="section-7"></a><p></p>
<h1>CONTRAINDICATIONS </h1>
<p class="First">PIPRACIL is contraindicated in patients with a history
of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> to any of the betalactams, including penicillins
and/or cephalosporins.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="s14"></a><a name="section-8"></a><p></p>
<h1>WARNINGS </h1>
<p class="First">SERIOUS AND OCCASIONALLY FATAL <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">HYPERSENSITIVITY</span> (ANAPHYLACTIC/ANAPHYLACTOID)
REACTIONS HAVE BEEN REPORTED IN PATIENTS ON PENICILLIN THERAPY. THESE
REACTIONS ARE MORE LIKELY TO OCCUR IN INDIVIDUALS WITH A HISTORY OF
PENICILLIN <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">HYPERSENSITIVITY</span> AND/OR A HISTORY OF SENSITIVITY TO MULTIPLE
ALLERGENS. THERE HAVE BEEN REPORTS OF INDIVIDUALS WITH A HISTORY OF
PENICILLIN <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">HYPERSENSITIVITY</span> WHO HAVE EXPERIENCED SEVERE REACTIONS
WHEN TREATED WITH CEPHALOSPORINS. BEFORE INITIATING THERAPY WITH PIPRACIL,
CAREFUL INQUIRY SHOULD BE MADE CONCERNING PREVIOUS <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">HYPERSENSITIVITY</span>
REACTIONS TO PENICILLINS, CEPHALOSPORINS OR OTHER ALLERGENS. IF AN
<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">ALLERGIC REACTION</span> OCCURS, PIPRACIL SHOULD BE DISCONTINUED AND APPROPRIATE
THERAPY INSTITUTED. <span class="Bold">SERIOUS ANAPHYLACTIC/ANAPHYLACTOID
REACTIONS REQUIRE IMMEDIATE EMERGENCY TREATMENT WITH EPINEPHRINE.
OXYGEN, INTRAVENOUS STEROIDS AND AIRWAY MANAGEMENT, INCLUDING INTUBATION,
SHOULD ALSO BE ADMINISTERED AS INDICATED.  </span></p>
<p><span class="Italics">Clostridium difficile</span> associated
<span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (CDAD) has been reported with use of nearly all antibacterial
agents, including PIPRACIL, and may range in severity from mild <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>
to fatal <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>. Treatment with antibacterial agents alters the normal
flora of the colon leading to overgrowth of <span class="Italics">C. difficile</span>.</p>
<p><span class="Italics">C. difficile</span> produces toxins A and B
which contribute to the development of CDAD. Hypertoxin producing
<span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">C. difficile  </span> cause
increased morbidity and mortality, as these <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> can be refractory
to antimicrobial therapy and may require colectomy. CDAD must be considered
in all patients who present with <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> following antibiotic use.
Careful medical history is necessary since CDAD has been reported
to occur over two months after the administration of antibacterial
agents.</p>
<p>If CDAD is suspected or confirmed, ongoing
antibiotic use not directed against <span class="Italics">C.
difficile</span> may need to be discontinued. Appropriate fluid
and electrolyte management, protein supplementation, antibiotic treatment
of <span class="Italics">C. difficile</span>, and surgical
evaluation should be instituted as clinically indicated.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="s15"></a><a name="section-9"></a><p></p>
<h1>PRECAUTIONS </h1>
<div class="Section" data-sectionCode="34072-9">
<a name="s16"></a><a name="section-9.1"></a><p></p>
<h2>General </h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> manifestations
have occurred in some patients receiving Î²-lactam antibiotics,
including piperacillin. These reactions have sometimes been associated
with abnormalities of coagulation tests such as clotting time, platelet
aggregation, and <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time and are more likely to occur in
patients with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>.</p>
<p>If <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> manifestations occur, the antibiotic should be discontinued
and appropriate therapy instituted.</p>
<p>The possibility of the emergence of resistant organisms which might
cause <span class="product-label-link" type="condition" conceptid="4105019" conceptname="Superimposed infection">superinfections</span> should be kept in mind, particularly during
prolonged treatment. If this occurs, appropriate measures should be
taken.</p>
<p>As with
other penicillins, patients may experience neuromuscular <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">excitability</span>
or <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> if higher than recommended doses are given intravenously.</p>
<p>PIPRACIL is a monosodium
salt containing 1.85Â mEq of Na<span class="Sup">+</span>Â perÂ g (42.5Â mg
of Na<span class="Sup">+</span>Â perÂ g). This should be considered when
treating patients requiring restricted salt intake. Periodic electrolyte
determinations should be made in patients with low potassium reserves,
and the possibility of <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> should be kept in mind with patients
who have potentially low potassium reserves and who are receiving
cytotoxic therapy or diuretics.</p>
<p><span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">Leukopenia</span> and <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> may occur during prolonged therapy.</p>
<p>As with other semisynthetic
penicillins, PIPRACIL therapy has been associated with an increased
incidence of <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> and <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> in <span class="product-label-link" type="condition" conceptid="441267" conceptname="Cystic fibrosis">cystic fibrosis</span> patients.</p>
<p>Prescribing PIPRACIL in
the absence of a proven or strongly suspected <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span>
or a <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> indication is unlikely to provide benefit to the
patient and increases the risk of the development of drug-resistant
bacteria.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="s17"></a><a name="section-9.2"></a><p></p>
<h2>Information for Patients</h2>
<p class="First">Patients should
be counseled that antibacterial drugs including PIPRACIL should only
be used to treat <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infections</span>. They do not treat <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infections</span>
(eg, the <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">common cold</span>). When PIPRACIL is prescribed to treat a bacterial
<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, patients should be told that although it is common to feel
better early in the course of therapy, the medication should be taken
exactly as directed. Skipping doses or not completing the full course
of therapy may (1) decrease the effectiveness of the immediate treatment
and (2) increase the likelihood that bacteria will develop resistance
and will not be treatable by PIPRACIL or other antibacterial drugs
in the future.</p>
<p><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> is a common problem
caused by antibiotics which usually ends when the antibiotic is discontinued.
Sometimes after starting treatment with antibiotics, patients can
develop watery and <span class="product-label-link" type="condition" conceptid="443530" conceptname="Hematochezia">bloody stools</span> (with or without <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach cramps</span> and
<span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>) even as late as two or more months after having taken the last
dose of antibiotic. If this occurs, patients should contact their
physician as soon as possible.</p>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="s18"></a><a name="section-9.3"></a><p></p>
<h2>Laboratory Tests</h2>
<p class="First">While piperacillin
possesses the characteristic low toxicity of the penicillin group
of antibiotics, periodic assessment of organ system functions, including
renal, hepatic, and hematopoietic, during prolonged therapy is advisable.</p>
<p>All patients with <span class="product-label-link" type="condition" conceptid="433417" conceptname="Gonorrhea">gonorrhea</span>
should have a serologic test for <span class="product-label-link" type="condition" conceptid="436033" conceptname="Syphilis">syphilis</span> at the time of diagnosis.
Patients treated with piperacillin should have a follow-up serologic
test for <span class="product-label-link" type="condition" conceptid="436033" conceptname="Syphilis">syphilis</span> after 3Â months.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="s19"></a><a name="section-9.4"></a><p></p>
<h2>Drug Interactions</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s20"></a><a name="section-9.4.1"></a><p></p>
<h3>Aminoglycosides</h3>
<p class="First">The mixing
of piperacillin with an aminoglycoside <span class="Italics">in vitro</span> can result in substantial inactivation of the
aminoglycoside.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s21"></a><a name="section-9.4.2"></a><p></p>
<h3>Vecuronium</h3>
<p class="First">When used
in the perioperative period, piperacillin has been implicated in the
prolongation of the <span class="product-label-link" type="condition" conceptid="4205421" conceptname="Neuromuscular block">neuromuscular blockade</span> of vecuronium. Caution
is indicated when piperacillin is used perioperatively. In one controlled
clinical study, the ureidopenicillins, including piperacillin, were
reported to prolong the action of vecuronium. Due to their similar
mechanism of action, it is expected that the <span class="product-label-link" type="condition" conceptid="4205421" conceptname="Neuromuscular block">neuromuscular blockade</span>
produced by any of the non-depolarizing muscle relaxants could be
prolonged in the presence of piperacillin.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s22"></a><a name="section-9.4.3"></a><p></p>
<h3>Probenecid</h3>
<p class="First">The oral
combination of probenecid before intramuscular injection of PIPRACIL
produces an increase in piperacillin peak serum level of about 30%.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s23"></a><a name="section-9.4.4"></a><p></p>
<h3>Anticoagulants</h3>
<p class="First">Coagulation
parameters should be tested more frequently and monitored regularly
during simultaneous administration of high doses of heparin, oral
anticoagulants, or other drugs that may affect the blood coagulation
system or the thrombocyte function.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s24"></a><a name="section-9.4.5"></a><p></p>
<h3>Methotrexate</h3>
<p class="First">Piperacillin
sodium may reduce the excretion of methotrexate. Therefore, serum
levels of methotrexate should be monitored in patients to avoid drug
toxicity.</p>
</div>
</div>
<div class="Section" data-sectionCode="34074-5">
<a name="s25"></a><a name="section-9.5"></a><p></p>
<h2>Drug/Laboratory Test Interactions</h2>
<p class="First">As with other penicillins,
the administration of PIPRACIL may result in a false-positive reaction
for glucose in the urine using a copper-reduction method. It is recommended
that glucose tests based on enzymatic glucose oxidase reactions be
used.</p>
<p>There
have been reports of positive test results using the Bio-Rad Laboratories
Platelia <span class="Italics">Aspergillus</span> EIA test
in patients receiving piperacillin/tazobactam injection who were subsequently
found to be free of <span class="Italics">Aspergillus</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. Cross-reactions with non-<span class="Italics">Aspergillus</span> polysaccharides and polyfuranoses with the
Bio-Rad Laboratories Platelia <span class="Italics">Aspergillus</span> EIA test have been reported.</p>
<p>Therefore, positive test results in patients receiving piperacillin
should be interpreted cautiously and confirmed by other diagnostic
methods.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="s26"></a><a name="section-9.6"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="e26"></a><a name="section-9.6.1"></a><p></p>
<h3>Carcinogenesis</h3>
<p class="First">Long-term
studies in animals have not been performed to evaluate carcinogenic
potential. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="e27"></a><a name="section-9.6.2"></a><p></p>
<h3>Mutagenesis</h3>
<p class="First">Piperacillin
was negative in the Ames <span class="Italics"><span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span></span> reversion test at concentrations up to 10Â Î¼g/plate. There
was no DNA damage in bacteria (Rec assay) exposed to piperacillin
at concentrations up to 200Â Î¼g/disc. In a mammalian point
mutation (mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> cells) assay, piperacillin was positive at
concentrations â‰¥Â 2500Â Î¼g/mL. Piperacillin was
negative in a cell (BALB/c-3T3) transformation assay at concentrations
up to 3000Â Î¼g/mL. <span class="Italics">In vivo</span>, piperacillin did not induce chromosomal aberrations in the bone
marrow cells of mice at I.V. doses up to 2000Â mg/kg/day or rats
at I.V. doses up to 1500Â mg/kg/day. These doses are half (mice)
or threeâ€‘fourths (rats) the maximum recommended human daily
dose based on body-surface area (mg/m<span class="Sup">2</span>). In another <span class="Italics">in vivo</span> test, there was no dominant
lethal effect when piperacillin was administered to rats at I.V. doses
up to 2000Â mg/kg/day, which is similar to the maximum recommended
human daily dose based on body-surface area (mg/m<span class="Sup">2</span>). When
piperacillin was administered to mice at I.V. doses up to 2000Â mg/kg/day,
which is half the maximum recommended human daily dose based on body-surface
area (mg/m<span class="Sup">2</span>), urine from these animals was not mutagenic
when tested in the Ames assay using <span class="Italics"><span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span></span> <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span> TA-98 in the absence of Î²-glucuronidase.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="e28"></a><a name="section-9.6.3"></a><p></p>
<h3>Impairment of Fertility</h3>
<p class="First">Reproduction
studies have been performed in mice (SQ) and rats (I.P.) and have
revealed no evidence of impaired fertility due to piperacillin administered
up to a dose which is half (mice) or similar (rats) to the maximum
recommended human daily dose based on body-surface area (mg/m<span class="Sup">2</span>). The plasma/serum concentrations at the highest daily dose
administered to rats in reproduction studies were comparable to the
maximum serum concentration seen in man, based on a toxicology study
in rats in which similar doses of piperacillin (in combination with
a betaâ€‘lactamase inhibitor, tazobactam) were administered I.P.and based on extrapolations from an animal pharmacokinetic study using
lower doses of piperacillin alone.</p>
</div>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="s27"></a><a name="section-9.7"></a><p></p>
<h2>Pregnancy </h2>
<div class="Section" data-sectionCode="34077-8">
<a name="e270"></a><a name="section-9.7.1"></a><p></p>
<h3>Teratogenic effectsâ€”Pregnancy Category B</h3>
<p class="First">Teratology
studies have been performed in mice (I.V.) and rats (I.V., I.P. and
SQ) and have revealed no evidence of harm to the fetus due to piperacillin
administered up to a dose which is approximately half the maximum
recommended human daily dose based on body-surface area (mg/m<span class="Sup">2</span>). In pharmacokinetic studies in pregnant and nonpregnant
rats, in which piperacillin was administered I.V. at a dose which
is half the maximum daily dose administered in teratology studies,
serum concentrations in rats were approximately 10 times the maximum
serum concentration seen in man. In other studies in mice and rats,
in which piperacillin (in combination with a beta-lactamase inhibitor,
tazobactam) was administered I.V. at approximately half the maximum
daily dose administered in teratology studies, plasma concentrations
of piperacillin were approximately 2 times (mice) and 5 times (rats)
the serum concentrations seen in man.</p>
<p>There are, however, no adequate and well-controlled studies with
piperacillin in pregnant women. Because animal reproduction studies
are not always predictive of the human response, this drug should
be used during pregnancy only if clearly needed.</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="s28"></a><a name="section-9.8"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">Piperacillin is excreted in low concentrations in
human milk. Caution should be exercised when PIPRACIL is administered
to nursing mothers.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="s29"></a><a name="section-9.9"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">Safety and effectiveness in pediatric patients have
not been established.</p>
<p>Data from published pharmacokinetics
studies indicate that the elimination half-life of piperacillin in
neonates is twofold to fourfold longer than that seen in pediatric
patients 1 month of age and above as well as in adults. In infants,
children, and adolescents, the elimination half-life of piperacillin
is shorter than that observed in adults. As in adults, the elimination
of piperacillin is decreased in pediatric patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>.
(See <span class="Bold"><a href="#s2">CLINICAL PHARMACOLOGY</a></span>.)</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="s30"></a><a name="section-9.10"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">Clinical studies of PIPRACIL did not include sufficient
numbers of subjects aged 65 and over to determine whether they respond
differently from younger subjects.</p>
<p>In general,
dose selection for an elderly patient should be cautious, usually
starting at the low end of the dosing range, reflecting the greater
frequency of decreased hepatic, renal, or cardiac function, and of
concomitant disease or other drug therapy.</p>
<p>PIPRACIL
contains 42.5Â mg (1.85Â mEq) of sodium per gram. At the usual
recommended doses, patients would receive between 255 and 765Â mg/day
(11.1 and 33.3Â mEq) of sodium. The geriatric population may respond
with a blunted natriuresis to salt loading. The total sodium content
from dietary and non-dietary sources may be clinically important with
regard to such diseases as <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>.</p>
<p>This drug is known to be substantially excreted by the kidney, and
the risk of toxic reactions to this drug may be greater in patients
with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. Because elderly patients are more likely
to have decreased renal function, care should be taken in dose selection,
and it may be useful to monitor renal function.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="s31"></a><a name="section-10"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">PIPRACIL is generally well tolerated. The most common
adverse reactions have been local in nature, following intravenous
or intramuscular injection. The following adverse reactions may occur:</p>
<p><span class="Italics">Local Reactions</span>: In clinical trials <span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">thrombophlebitis</span> was noted in 4% of patients.
<span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span>, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, and/or <span class="product-label-link" type="condition" conceptid="4165876" conceptname="Induration">induration</span> at the injection site occurred in
2% of patients. Less frequent reactions including <span class="product-label-link" type="condition" conceptid="4118793" conceptname="Ecchymosis">ecchymosis</span>, deep
vein <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span>, and <span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">hematomas</span> have also occurred.</p>
<p><span class="Italics">Gastrointestinal</span>: <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span>
and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">loose stools</span> were noted in 2% of patients. Other less frequent
reactions included <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, increases in liver enzymes (LDH,
AST, ALT), <span class="product-label-link" type="condition" conceptid="4032334" conceptname="Hyperbilirubinemia">hyperbilirubinemia</span>, <span class="product-label-link" type="condition" conceptid="4318541" conceptname="Cholestatic hepatitis">cholestatic hepatitis</span>, <span class="product-label-link" type="condition" conceptid="4318833" conceptname="Hemorrhagic diarrhea">bloody diarrhea</span>,
and <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">pseudomembranous colitis</span>. The onset of <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">pseudomembranous colitis</span>
symptoms may occur during or after antibiotic treatment. (See <span class="Bold"><a href="#s14">WARNINGS</a></span>.)</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span>
Reactions</span>: Anaphylactic/<span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span> (some leading
to <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span> and fatalities) have been reported. (See <span class="Bold"><a href="#s14">WARNINGS</a></span>.)</p>
<p><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span> was noted in 1% of patients. Other
less frequent findings included <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="4196499" conceptname="Vesicular eruption">vesicular eruptions</span>, and
positive Coombs tests.</p>
<p>Other dermatologic manifestations,
such as <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>
and <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, have been reported.</p>
<p><span class="Italics">Renal</span>: Elevations of creatinine
or BUN, <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span> and interstitial <span class="product-label-link" type="condition" conceptid="193253" conceptname="Nephritis">nephritis</span> have been reported.</p>
<p><span class="Italics">Central Nervous System</span>: <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, and <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> have been reported.</p>
<p><span class="Italics">Hemic and Lymphatic</span>: <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">Hemolytic anemia</span>, <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>, <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span>, prolonged <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>
time, reversible <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, and/or
<span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span> have been reported. As with other Î²-lactam antibiotics,
reversible <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span> (<span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>) is more apt to occur in patients
receiving prolonged therapy at high dosages or in association with
drugs known to cause this reaction.</p>
<p><span class="Italics">Serum Electrolytes</span>: Individuals with
liver disease or individuals receiving cytotoxic therapy or diuretics
were reported to demonstrate a decrease in serum potassium concentrations
with high doses of piperacillin. <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span> has been reported.</p>
<p><span class="Italics">Skeletal</span>: Prolonged
<span class="product-label-link" type="condition" conceptid="4002033" conceptname="Muscle relaxation">muscle relaxation</span> (see <span class="Bold"><a href="#s15">PRECAUTIONS</a></span>,<span class="Bold"><a href="#s19"> Drug Interactions</a></span>).</p>
<p><span class="Italics">Other</span>: <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span>, <span class="product-label-link" type="condition" conceptid="4105019" conceptname="Superimposed infection">superinfection</span>,
including <span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">candidiasis</span>; hemorrhagic manifestations have been reported.</p>
<p>Piperacillin therapy has been associated with an increased
incidence of <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> and <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> in <span class="product-label-link" type="condition" conceptid="441267" conceptname="Cystic fibrosis">cystic fibrosis</span> patients.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="s32"></a><a name="section-11"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">There is no specific information on <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> with
PIPRACIL. Other penicillin-class drugs in overdosage, however, have
the potential to cause neuromuscular hyperirritability or convulsive
<span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>. In case of overdosage, discontinue medication, treat symptomatically,
and institute supportive measures as required. Piperacillin can be
removed by hemodialysis but not peritoneal dialysis.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="s33"></a><a name="section-12"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">PIPRACIL may be administered by the intramuscular
route (see NOTE) or intravenously as a three- to five-minute intravenous
injection or as a 20- to 30-minute infusion. The usual dosage of PIPRACIL
for serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> is 3Â to 4Â g given every four to six
hours as a 20- to 30-minute infusion. For serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, the
intravenous route should be used.</p>
<p>PIPRACIL should
not be mixed with an aminoglycoside in a syringe or infusion bottle
since this can result in inactivation of the aminoglycoside.</p>
<p>The maximum daily dose for adults is usually 24Â g/day,
although higher doses have been used.</p>
<p>Intramuscular
injections (see NOTE) should be limited to 2 g per injection site.
This route of administration has been used primarily in the treatment
of patients with uncomplicated <span class="product-label-link" type="condition" conceptid="433417" conceptname="Gonorrhea">gonorrhea</span> and <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infections</span>.</p>
<a name="t300"></a><table width="100.00%">
<caption><span>DOSAGE RECOMMENDATIONS </span></caption>
<col align="left" width="50.000%">
<col align="left" width="50.000%">
<thead><tr class="First Last">
<th align="left" valign="top"><span class="Bold">Type of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span></span></th>
<th align="left" valign="top"><span class="Bold">Usual Total
Daily Dose</span></th>
</tr></thead>
<tfoot><tr class="First Last"><td align="left" colspan="2" valign="top"><p class="First Footnote"><span class="Sup">â€ </span>OneÂ g of probenecid should be given orally
one-half hour prior to injection.</p></td></tr></tfoot>
<tbody>
<tr class="First">
<td align="left" valign="top">Serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> such as <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">septicemia</span>,
<span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">nosocomial pneumonia</span>, intra-<span class="product-label-link" type="condition" conceptid="4028062" conceptname="Infectious disease of abdomen">abdominal infections</span>, aerobic and anaerobic
gynecologic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, and skin and <span class="product-label-link" type="condition" conceptid="4320030" conceptname="Soft tissue infection">soft tissue infections</span><br>
</td>
<td align="left" valign="top">12 â€“ 18Â g/d I.V. (200 â€“
300Â mg/kg/d) in divided doses every 4 to 6Â h </td>
</tr>
<tr>
<td align="left" valign="top">Complicated <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infections</span> </td>
<td align="left" valign="top">8 â€“ 16Â g/d I.V. (125 â€“
200Â mg/kg/d) in divided doses every 6 to 8 h </td>
</tr>
<tr>
<td align="left" valign="top">Uncomplicated <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infections</span>
and most community-acquired <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> </td>
<td align="left" valign="top">6 â€“ 8Â g/d I.M. or I.V. (100â€“ 125Â mg/kg/d) in divided doses every 6 to 12Â h </td>
</tr>
<tr class="Last">
<td align="left" valign="top">Uncomplicated <span class="product-label-link" type="condition" conceptid="433417" conceptname="Gonorrhea">gonorrhea</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> </td>
<td align="left" valign="top">2 g I.M.<span class="Sup">â€ </span> as a one-time
dose </td>
</tr>
</tbody>
</table>
<p>The average duration of PIPRACIL treatment is from
seven to ten days, except in the treatment of gynecologic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>,
which is from three to ten days; the duration should be guided by
the patient's clinical and bacteriological progress. For most
acute <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, treatment should be continued for at least 48 to
72 hours after the patient becomes asymptomatic. Antibiotic therapy
for <span class="Italics">S. pyogenes</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>
should be maintained for at least ten days to reduce the risk of rheumatic
<span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>.</p>
<p>When PIPRACIL is given concurrently with
aminoglycosides, both drugs should be used in full therapeutic doses.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s34"></a><a name="section-12.1"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<a name="t301"></a><table rules="all" width="100.00%">
<caption><span>Dosage
in <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span></caption>
<col align="left" width="25.000%">
<col align="left" width="25.000%">
<col align="left" width="25.000%">
<col align="left" width="25.000%">
<thead><tr class="First Last">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">Creatinine<br>Clearance<br>mL/min </td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">Urinary Tract<br><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span><br>(uncomplicated) </td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">Urinary Tract<br><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span><br>(complicated) </td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">Serious<br>Systemic<br><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span> </td>
</tr></thead>
<tbody>
<tr class="Botrule First Lrule Rrule Toprule">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">&gt;40 </td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="3" valign="top">No dosage adjustment necessary </td>
</tr>
<tr class="Botrule Lrule Rrule Toprule">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">20-40 </td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">No dosage adjustment necessary </td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">9Â g/day<br>3Â g every 8 h </td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">12Â g/day<br>4Â g every 8 h </td>
</tr>
<tr class="Botrule Last Lrule Rrule Toprule">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">&lt;20 </td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">6Â g/day<br>3Â g every 12 h </td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">6Â g/day<br>3Â g every 12 h </td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">8Â g/day<br>4Â g every 12 h </td>
</tr>
</tbody>
</table>
<p class="First">For patients on hemodialysis, the maximum daily
dose is 6Â g/day (2Â g every 8 hours). In addition, because
hemodialysis removes 30% to 50% of piperacillin in 4 hours, a 1-g
additional dose should be administered following each dialysis period.</p>
<p>For patients with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span> and <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic insufficiency</span>,
measurement of serum levels of piperacillin will provide additional
guidance for adjusting dosage.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s35"></a><a name="section-12.2"></a><p></p>
<h2>Prophylaxis</h2>
<p class="First">When possible, PIPRACIL should be administered as
a 20- to 30-minute infusion just prior to anesthesia. Administration
while the patient is awake will facilitate identification of possible
adverse reactions during drug infusion. (See <span class="Bold"><a href="#s19">PRECAUTION, Drug Interactions</a></span><span class="Bold"></span>.)</p>
<table rules="all" width="100.00%">
<col align="left" width="25.000%">
<col align="left" width="25.000%">
<col align="left" width="25.000%">
<col align="left" width="25.000%">
<thead><tr class="First Last">
<td align="center" valign="top"><span class="Bold">INDICATION</span></td>
<td align="center" valign="top"><span class="Bold">1<span class="Sup">st </span> Dose</span></td>
<td align="center" valign="top"><span class="Bold">2<span class="Sup">nd </span> Dose</span></td>
<td align="center" valign="top"><span class="Bold">3<span class="Sup">rd </span> Dose</span></td>
</tr></thead>
<tbody>
<tr class="First">
<td class="Lrule Rrule" align="left" valign="top">Intra-abdominal<br>Â Â Surgery </td>
<td class="Rrule" align="left" valign="top">2Â g I.V. just
prior to surgery </td>
<td class="Rrule" align="left" valign="top">2Â g during surgery </td>
<td class="Rrule" align="left" valign="top">2Â g every 6Â h
Post-Op for no more than 24Â h </td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">Vaginal<br>Â Â Hysterectomy </td>
<td class="Rrule" align="left" valign="top">2Â g I.V. just
prior to surgery </td>
<td class="Rrule" align="left" valign="top">2Â g 6 h after
1<span class="Sup">st </span> dose </td>
<td class="Rrule" align="left" valign="top">2Â g 12Â h
after 1<span class="Sup">st </span> dose </td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">Cesarean<br>Â Â Section </td>
<td class="Rrule" align="left" valign="top">2Â g I.V. after
cord is clamped </td>
<td class="Rrule" align="left" valign="top">2Â g 4 h after
1<span class="Sup">st </span> dose </td>
<td class="Rrule" align="left" valign="top">2Â g 8Â h
after 1<span class="Sup">st </span> dose </td>
</tr>
<tr class="Last">
<td class="Lrule" align="left" valign="top">Abdominal<br>Â Â Hysterectomy </td>
<td class="Lrule Rrule" align="left" valign="top">2Â g I.V.
just prior to surgery </td>
<td class="Rrule" align="left" valign="top">2Â g on return
to recovery room </td>
<td class="Rrule" align="left" valign="top">2Â g after 6Â h </td>
</tr>
</tbody>
</table>
<div class="Section" data-sectionCode="42229-5">
<a name="e35"></a><a name="section-12.2.1"></a><p></p>
<h3></h3>
<p class="First"><span class="Italics">Pediatric patients.</span> Dosages in pediatric patients under 12 years of age have not been
studied in adequate and well-controlled clinical trials (See <span class="Bold"><a href="#s2">CLINICAL PHARMACOLOGY</a></span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="e36"></a><a name="section-12.2.2"></a><p></p>
<h3></h3>
<a name="t302"></a><table rules="rows" width="100.00%">
<col align="left" width="50.000%">
<col align="left" width="50.000%">
<tfoot><tr class="First Last"><td align="left" colspan="2" valign="top"><p class="First Footnote"><span class="Sup">Â¶</span>Either Parabens or Benzyl Alcohol.<br><span class="Sup">#</span>For Intramuscular Use Only. Lidocaine is contraindicated in patients
with a known history of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to local anesthetics of the
amide type.</p></td></tr></tfoot>
<tbody class="Headless">
<tr class="First"><td align="center" colspan="2" valign="top"><span class="Bold">PRODUCT RECONSTITUTION/DOSAGE PREPARATION</span></td></tr>
<tr><td align="left" colspan="2" valign="top"><span class="Bold">Conventional
Vials:</span></td></tr>
<tr><td align="center" colspan="2" valign="top"><span class="Bold">Diluents for Reconstitution</span></td></tr>
<tr class="Last">
<td align="left" valign="top">Sterile Water for Injection <br>Bacteriostatic<span class="Sup">Â¶</span> Water for Injection </td>
<td align="left" valign="top">Sodium Chloride Injection<br>Bacteriostatic<span class="Sup">Â¶</span> Sodium Chloride Injection <br>Dextrose 5% in Water <br>Dextrose 5% and 0.9% Sodium Chloride <br>Lidocaine<span class="Sup">#</span> HCl
0.5-1% (without epinephrine) </td>
</tr>
</tbody>
</table>
<table rules="rows" width="100.00%">
<col align="left" width="50.000%">
<col align="left" width="50.000%">
<tfoot><tr class="First Last"><td align="left" colspan="2" valign="top"><p class="First Footnote"><span class="Sup">â€ â€ </span>When PIPRACIL<span class="Sup">Â®</span>is further diluted
with Lactated Ringer's Injection, the diluted solution must be
administered within 2 hours.</p></td></tr></tfoot>
<tbody class="Headless">
<tr class="First"><td align="left" colspan="2" valign="top"><span class="Bold">Conventional
Vials:  </span></td></tr>
<tr>
<td align="left" valign="top"><span class="Bold">Intravenous Solutions </span></td>
<td align="left" valign="top"><span class="Bold">Intravenous Admixtures </span></td>
</tr>
<tr class="Last">
<td align="left" valign="top">Dextrose 5% in Water <br>0.9% Sodium
Chloride <br>Dextrose 5% and 0.9% Sodium Chloride <br>Lactated Ringer's
Injection<span class="Sup">â€ â€ </span><br>Dextran 6% in 0.9% Sodium
Chloride </td>
<td align="left" valign="top">Normal Saline [+Â KClÂ 40Â mEq]<br>5% Dextrose in Water [+Â KClÂ 40Â mEq]<br>5% Dextrose/Normal
Saline [+Â KClÂ 40Â mEq]<br>Ringer's Injection
[+Â KClÂ 40Â mEq]<br>Lactated Ringer's Injection
[+Â KClÂ 40Â mEq]<span class="Sup">â€ â€ </span>
</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s36"></a><a name="section-12.3"></a><p></p>
<h2>Intravenous Administration </h2>
<p class="First"><span class="Italics">Reconstitution Directions
for Conventional Vials: </span> Reconstitute each gram of PIPRACIL
with at least 5Â mL of a suitable diluent (except Lidocaine HCl
0.5%-1% without epinephrine) listed above. Shake well until dissolved.
Reconstituted solution may be diluted to the desired volume (eg, 50
or 100Â mL) in the above listed intravenous solutions and admixtures.</p>
<p>DIRECTIONS FOR ADMINISTRATION<br><span class="Italics">Intermittent IV Infusion</span><br>Infuse
diluted solution over period of about 30 minutes. During infusion,
it is desirable to discontinue the primary intravenous solution.</p>
<p><span class="Italics">Intravenous Injection (Bolus)</span><br>Reconstituted solution should be injected slowly over a 3-to
5-minute period to help avoid vein irritation.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s37"></a><a name="section-12.4"></a><p></p>
<h2>Intramuscular Administration</h2>
<span class="Bold">(Conventional Vials Only)</span><p class="First"><span class="Italics">Reconstitution Directions:</span>Reconstitute each gram of PIPRACIL with 2 mL of a suitable diluent
listed above to achieve a concentration of 1 g per 2.5Â mL. Shake
well until dissolved.</p>
<p>DIRECTIONS FOR ADMINISTRATION<br>When indicated by clinical and bacteriological findings, intramuscularadministration of 6 to 8Â g daily of PIPRACIL, in divided doses,
may be utilized for initiation of therapy. In addition, intramuscular
administration of the drug may be considered for maintenance therapy
after clinical and bacteriologic improvement has been obtained with
intravenous piperacillin sodium treatment. Intramuscular administration
should not exceed 2 g per injection at any one site.</p>
<p>The preferred site is the upper outer quadrant of the buttock (ie, <span class="Italics">gluteus maximus</span>).</p>
<p>The deltoid area should be used only if well-developed, and then
only with caution to avoid <span class="product-label-link" type="condition" conceptid="136865" conceptname="Injury of radial nerve">radial nerve injury</span>. Intramuscular injections
should not be made into the lower or mid-third of the upper arm.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s38"></a><a name="section-12.5"></a><p></p>
<h2>Stability of PIPRACIL Following Reconstitution</h2>
<p class="First">PIPRACIL is stable in both glass and plastic containers
when reconstituted with recommended diluents and when diluted with
the intravenous solutions and intravenous admixtures indicated above.</p>
<p>Pharmacy vials should be used immediately after reconstitution.
Discard any unused portion after 24 hours if stored at room temperature
(20Â° to 25Â°C [68Â° to 77Â°F]), or after 48 hours
if stored at refrigerated temperature (2Â°Â toÂ 8Â°CÂ [36Â°Â toÂ 46Â°F]).
Vials should not be frozen after reconstitution.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="s39"></a><a name="section-13"></a><p></p>
<h1>How Supplied </h1>
<p class="First">PIPRACIL<span class="Sup">Â®</span> (piperacillin for injection)
is available in vials containing freeze-dried piperacillin sodium
powder equivalent to two, three, and four g of piperacillin. OneÂ g
of piperacillin (as a monosodium salt) contains 1.85Â mEq (42.5Â mg)
of sodium. </p>
<p><span class="Bold">Product
Numbers</span><br>2 gram/Vial-10 per box-NDC 0206-3879-16<br>3
gram/Vial-10 per box-NDC 0206-3882-55<br>4 gram/Vial-10 per box-NDC
0206-3880-25</p>
<p><span class="Bold">Store
at controlled room temperature 20</span>Â°<span class="Bold">C-25Â°C</span><span class="Bold">(68Â°F-77Â°F).</span></p>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="s40"></a><a name="section-14"></a><p></p>
<h1>REFERENCES </h1>
<p class="First"><span class="Sup">1</span><span><a name="endnote1"></a>National </span>Committee for Clinical Laboratory
Standards. Methods for Dilution Antimicrobial Susceptibility Tests
for Bacteria that Grow Aerobically â€“ Fifth Edition. Approved
Standard NCCLS Document M7-A5, Vol. 20, No. 2, NCCLS, Wayne, PA, January,
2000.</p>
<p><span class="Sup">2</span><span><a name="endnote2"></a>National </span>Committee for Clinical Laboratory Standards. Performance Standards
for Antimicrobial Susceptibility Testing â€“ Eleventh Informational
Supplement. NCCLS Document M100-S11, Vol. 21, No. 1, NCCLS, Wayne,
PA, January, 2001.</p>
<p><span class="Sup">3</span><span><a name="endnote3"></a>National</span> Committee for Clinical Laboratory
Standards. Performance Standards for Antimicrobial Disk Susceptibility
Tests â€“ Seventh Edition. Approved Standard NCCLS Document M2-A7,
Vol. 20, No. 1, NCCLS, Wayne, PA, January, 2000.</p>
<p><span class="Sup">4</span><span><a name="endnote4"></a>National </span>Committee
for Clinical Laboratory Standards. Methods for Antimicrobial Susceptibility
Testing of Anaerobic Bacteria â€“ Fifth Edition. Approved Standard
NCCLS Document M11-A5, Vol. 21, No. 2, NCCLS, Wayne, PA, March, 2001.</p>
<p><span class="Bold">Wyeth</span><span class="Sup">Â®</span></p>
<p>Wyeth Pharmaceuticals Inc.<br>Philadelphia,
PA 19101</p>
<p>W10440C007<br>ET01<br>Rev 03/07</p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>PIPRACILÂ 		
					</strong><br><span class="contentTableReg">piperacillin sodium injection, powder, lyophilized, for solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0206-3879</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS, INTRAMUSCULAR</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Piperacillin Sodium</strong> (Piperacillin) </td>
<td class="formItem"></td>
<td class="formItem">2Â g</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0206-3879-16</td>
<td class="formItem">10  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1  in 1 VIAL</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>PIPRACILÂ 		
					</strong><br><span class="contentTableReg">piperacillin sodium injection, powder, lyophilized, for solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0206-3882</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS, INTRAMUSCULAR</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Piperacillin Sodium</strong> (Piperacillin) </td>
<td class="formItem"></td>
<td class="formItem">3Â g</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0206-3882-55</td>
<td class="formItem">10  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1  in 1 VIAL</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>PIPRACILÂ 		
					</strong><br><span class="contentTableReg">piperacillin sodium injection, powder, lyophilized, for solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0206-3880</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS, INTRAMUSCULAR</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Piperacillin Sodium</strong> (Piperacillin) </td>
<td class="formItem"></td>
<td class="formItem">4Â g</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0206-3880-25</td>
<td class="formItem">10  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1  in 1 VIAL</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Wyeth Pharmaceuticals, Inc.</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 4/2007<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>6DF9BFF6-C919-CBB2-24C6-AC873AF37E28</div>
<div>Set id: FAC0C875-111E-4AF2-D186-ED4D4EE9DE59</div>
<div>Version: 2</div>
<div>Effective Time: 20070424</div>
</div>
</div>Â <div class="DistributorName">Wyeth Pharmaceuticals, Inc.</div></p>
</body></html>
